HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

CX-2029

A CD71-targeting Probody–drug conjugate (PDC) composed of a protease-activatable antibody prodrug targeting the TfR1 conjugated to the cytotoxin monomethyl auristatin E.

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Badagnani, Ilaria: 1 article (01/2022)
2.	Belvin, Marcia: 1 article (01/2022)
3.	Buchanan, Fritz: 1 article (01/2022)
4.	Chauhan, Niharika: 1 article (01/2022)
5.	Desnoyers, Luc: 1 article (01/2022)
6.	DuPage, Amy: 1 article (01/2022)
7.	Duvur, Shanti: 1 article (01/2022)
8.	Elkins, Kristi: 1 article (01/2022)
9.	Henriques, Tracy: 1 article (01/2022)
10.	Huang, Yuanhui: 1 article (01/2022)

Related Diseases

1.

Neoplasms (Cancer)

01/01/2021 - "Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies."
01/01/2022 - "These data support further clinical development of the anti-CD71 PDC CX-2029 as a novel cancer therapeutic."
01/01/2021 - "PROCLAIM-CX-2029 is a phase I first-in-human study of CX-2029, a Probody-drug conjugate targeting CD71 (transferrin receptor 1) in adults with advanced solid tumors. "
01/01/2021 - "CX-2029 is a masked form of a proprietary anti-CD71 antibody conjugated to monomethyl auristatin E, designed to be unmasked in the tumor microenvironment by tumor-associated proteases, therefore limiting off-tumor toxicity and creating a therapeutic window for this previously undruggable target. "
01/01/2022 - "CX-2029, a Pb-Tx conjugated to maleimido-caproyl-valine-citrulline-p-aminobenzyloxycarbonyl-monomethyl auristatin E, was developed as a novel cancer therapeutic targeting CD71. "

Related Drugs and Biologics

1.	Transferrin Receptors (Transferrin Receptor)
2.	monomethyl auristatin E
3.	Valine (L-Valine)
4.	Peptide Hydrolases (Proteases)
5.	Citrulline